Mainz Biomed Bets on Pancreatic Cancer in High-Stakes Pivot

BERKELEY, CA and MAINZ, Germany – February 17, 2026 – In a dramatic strategic overhaul, molecular genetics company Mainz Biomed N.V. announced it has secured a $6.0 million private placement and will pivot its focus entirely to the development of its pancreatic cancer screening test in the United States. The move involves selling off its flagship colorectal cancer assets, winding down its German operations, and installing a new chairman known for corporate turnarounds.

The series of transactions provides a critical financial lifeline for the Nasdaq-listed company (MYNZ) and marks a profound shift away from its established European business toward a riskier, early-stage venture in the highly competitive U.S. diagnostics market.

A Financial Lifeline and a New Helmsman

At the core of the restructuring is a $6.0 million private placement from investor David Lazar, who was simultaneously appointed Chairman of the Board of Directors. The financing is structured as Convertible Non-Redeemable Preferred Stock and will be delivered in two equal tranches of $3.0 million. The first tranche closed on February 13, with the second expected before April 15, 2026, pending stockholder approval.

This injection of capital is intended to fund ongoing operations, settle outstanding liabilities, and provide the company with what Lazar described as “critical runway and stability.” Lazar is a private investor specializing in what he calls “Turnaround Situations” with distressed public companies. Through his firms, Activist Investing LLC and Custodian Ventures LLC, he has built a reputation for taking active roles in companies that have fallen out of favor with Wall Street, aiming to unlock hidden value through governance reform and strategic repositioning.

“Our immediate focus is to continue to further develop and evaluate opportunities to grow our pancreatic screening program in the U.S. and stabilize the business,” Lazar stated in the announcement. “At the same time, we will be disciplined and thoughtful as we explore additional strategic alternatives that can unlock long-term value for stockholders.”

Lazar's appointment, though temporary until the next general meeting, signals a clear directive from the new capital source: stabilize the finances and execute a rapid, decisive pivot.

The High-Stakes Pivot from ColoAlert to PancAlert

The company’s new direction represents a high-stakes gamble. Mainz Biomed is stepping away from its primary revenue-generating asset, ColoAlert®, a non-invasive and easy-to-use diagnostic test for colorectal cancer that is already marketed across Europe. The company had been actively expanding its reach, recently adding ColoAlert to the digital health platform DoctorBox in Germany and signing a deal in late 2025 to introduce the test to South America. Furthermore, it has been running a clinical study, eAArly DETECT 2, in preparation for seeking FDA approval in the U.S.

Now, the company plans to sell its entire colorectal cancer screening business, including the ColoAlert brand and associated assets. According to the press release, discussions are already underway with several interested parties. This decision effectively abandons a commercial-stage product with a foothold in the European market.

In its place, Mainz Biomed is channeling all its resources into PancAlert, an early-stage screening test for pancreatic cancer. PancAlert is a candidate product that uses PCR-based technology to detect molecular-genetic biomarkers in blood and stool samples. While the company presented promising results from a verification study at the American Association for Cancer Research (AACR) annual meeting in January 2026, the product remains in the developmental phase, far from commercialization and facing a lengthy and expensive regulatory pathway in the U.S.

Unwinding European Operations to Fuel U.S. Ambitions

To support this strategic shift and conserve capital, Mainz Biomed will wind down its German subsidiary. This move is designed to significantly reduce operating expenses, thereby extending the financial runway provided by the new $6.0 million investment. While the full operational and legal ramifications of shuttering its German base are not yet public, the decision underscores a complete withdrawal from its European market presence.

The cost-cutting measure is essential for a company transitioning from a commercial product to a research-and-development focus. The burn rate associated with developing and running clinical trials for a new diagnostic in the U.S. is substantial, and the funds from the private placement, combined with savings from the operational shutdown, are crucial to seeing the PancAlert program through its next critical milestones.

The sale of the ColoAlert assets, if successful, could provide an additional, non-dilutive source of funding to further bolster the company's balance sheet as it navigates this transition.

Reshaping the Cancer Diagnostics Landscape

Mainz Biomed's decision sends ripples through the cancer diagnostics market. The planned divestiture of ColoAlert opens an opportunity for a competitor to acquire an established brand in the European colorectal cancer screening space. Depending on the buyer, this could consolidate market share or introduce a new player to the field.

Meanwhile, the company’s all-in bet on pancreatic cancer highlights the immense unmet need and potential commercial reward in that sector. Pancreatic cancer is notoriously difficult to detect early, leading to poor prognoses for most patients. An accurate, non-invasive screening test could become a blockbuster product and fundamentally change clinical practice. However, this field is fraught with scientific and regulatory challenges, and numerous companies are racing to develop a reliable solution.

By shedding its existing business, Mainz Biomed transforms into a leaner, more focused entity singularly dedicated to cracking the code of early pancreatic cancer detection. The company's future now hinges entirely on the success of its PancAlert program and the strategic vision of its new leadership. Investors and the broader medical community will be watching closely to see if this high-risk pivot can transform the struggling company into a leader in one of oncology's most challenging frontiers.